Insmed (INSM) Other Operating Expenses (2011 - 2026)
Insmed (INSM) posted quarterly Other Operating Expenses of $2.5 million for Q1 2026, down 93.78% year-over-year from $40.8 million in Q1 2025, and down 97.81% quarter-over-quarter from $116.2 million in Q4 2025.
Insmed (INSM) Other Operating Expenses (2011 - 2026) Analysis & Trends
Insmed's Other Operating Expenses history runs 12 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Other Operating Expenses fell 93.78% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $342.6 million (up 58.26% YoY), while the FY2025 annual figure was $380.9 million, up 108.76% from the prior year.
- Other Operating Expenses for Q1 2026 stood at $2.5 million, down from $116.2 million in the prior quarter.
- The five-year high for Other Operating Expenses was $135.6 million in Q3 2025, with the low at $1.8 million in Q1 2022.
- The 5-year median for Other Operating Expenses is $27.0 million (2023), against an average of $41.4 million.
- The sharpest annual moves came in 2025 and 2026: Other Operating Expenses jumped 821.17% in 2025, then plunged 93.78% in 2026.
- Insmed's Other Operating Expenses stood at $12.5 million in 2022, then soared by 182.5% to $35.4 million in 2023, then tumbled by 64.37% to $12.6 million in 2024, then surged by 821.17% to $116.2 million in 2025, then sank by 97.81% to $2.5 million in 2026.
- Business Quant data shows INSM's Other Operating Expenses at $2.5 million in Q1 2026, $116.2 million in Q4 2025, and $135.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.47 Mn |
| Mar 31, 2026 | 2.54 Mn |
| Dec 31, 2025 | 116.20 Mn |
| Sep 30, 2025 | 135.56 Mn |
| Jun 30, 2025 | 88.34 Mn |
| Mar 31, 2025 | 40.84 Mn |
| Dec 31, 2024 | 12.61 Mn |
| Sep 30, 2024 | 37.12 Mn |
| Jun 30, 2024 | 125.93 Mn |
| Mar 31, 2024 | 6.82 Mn |
| Dec 31, 2023 | 35.41 Mn |
| Sep 30, 2023 | 26.97 Mn |
| Jun 30, 2023 | 31.36 Mn |
| Mar 31, 2023 | 5.59 Mn |
| Dec 31, 2022 | 12.53 Mn |
| Sep 30, 2022 | 19.97 Mn |
| Jun 30, 2022 | 5.04 Mn |
| Mar 31, 2022 | 1.84 Mn |
| Dec 31, 2021 | 13.58 Mn |
| Sep 30, 2021 | 19.75 Mn |